Cargando…

CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies

Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Prieto-Torres, Lucia, Rodriguez-Pinilla, Socorro M., Onaindia, Arantza, Ara, Mariano, Requena, Luis, Piris, Miguel Á.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355473/
https://www.ncbi.nlm.nih.gov/pubmed/30630983
http://dx.doi.org/10.3324/haematol.2018.197152
_version_ 1783391339050696704
author Prieto-Torres, Lucia
Rodriguez-Pinilla, Socorro M.
Onaindia, Arantza
Ara, Mariano
Requena, Luis
Piris, Miguel Á.
author_facet Prieto-Torres, Lucia
Rodriguez-Pinilla, Socorro M.
Onaindia, Arantza
Ara, Mariano
Requena, Luis
Piris, Miguel Á.
author_sort Prieto-Torres, Lucia
collection PubMed
description Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Here, we review the most significant genetic, epigenetic and molecular alterations described to date in primary cutaneous CD30-positive T-cell lymphoproliferative disorders, and their potential as therapeutic targets.
format Online
Article
Text
id pubmed-6355473
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Ferrata Storti Foundation
record_format MEDLINE/PubMed
spelling pubmed-63554732019-02-14 CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies Prieto-Torres, Lucia Rodriguez-Pinilla, Socorro M. Onaindia, Arantza Ara, Mariano Requena, Luis Piris, Miguel Á. Haematologica Review Article Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Here, we review the most significant genetic, epigenetic and molecular alterations described to date in primary cutaneous CD30-positive T-cell lymphoproliferative disorders, and their potential as therapeutic targets. Ferrata Storti Foundation 2019-02 /pmc/articles/PMC6355473/ /pubmed/30630983 http://dx.doi.org/10.3324/haematol.2018.197152 Text en Copyright © 2019 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.
spellingShingle Review Article
Prieto-Torres, Lucia
Rodriguez-Pinilla, Socorro M.
Onaindia, Arantza
Ara, Mariano
Requena, Luis
Piris, Miguel Á.
CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies
title CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies
title_full CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies
title_fullStr CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies
title_full_unstemmed CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies
title_short CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies
title_sort cd30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355473/
https://www.ncbi.nlm.nih.gov/pubmed/30630983
http://dx.doi.org/10.3324/haematol.2018.197152
work_keys_str_mv AT prietotorreslucia cd30positiveprimarycutaneouslymphoproliferativedisordersmolecularalterationsandtargetedtherapies
AT rodriguezpinillasocorrom cd30positiveprimarycutaneouslymphoproliferativedisordersmolecularalterationsandtargetedtherapies
AT onaindiaarantza cd30positiveprimarycutaneouslymphoproliferativedisordersmolecularalterationsandtargetedtherapies
AT aramariano cd30positiveprimarycutaneouslymphoproliferativedisordersmolecularalterationsandtargetedtherapies
AT requenaluis cd30positiveprimarycutaneouslymphoproliferativedisordersmolecularalterationsandtargetedtherapies
AT pirismiguela cd30positiveprimarycutaneouslymphoproliferativedisordersmolecularalterationsandtargetedtherapies